Huntington’s Disease

Hungtington’s Disease, also reffered to as “Hungtington’s Chorea”, is a neurodegenerative hereditary rare disease. Symptoms include motor, cognitive and psychiatric impairment resulting from neurodegeneration characteristic of the diseasing, ineluctably evolving to autonomy loss and death.

Hungtington’s Disease is caused by a single dominant defective gene on chromosome 4. An individual inheriting the gene from a parent will thus eventually develop the disease.

For the time being, no cure is available to teat Hungtington’s Disease or to slow down or stop cognitive, motor and psychiatric progression of the disease. Current therapies focus on helping patients managing symptoms.

Assays and models of Hungtington’s Disease

in vitro models

  • Neuroservice, our member expert in cell and slice electrophysiology, offers:
    • Extensive experience in slice electrophysiology on HD models.
    • Electrophysiology assays on iPSC-derived neurons from HD patients

in vivo models

  • Key-Obs, our expert in behavioural models of neurological disorders, proposes test for behavioural investigations on HD models
  • Motac, our expert platform specialized in providing new technologies to develop therapies for NDDs, provides Kinematic Assessments assays on NHP. 

Are you currently working on compounds targeting Hungtington’s Disease?

Please contact us for any additional information and we will gladly come back to you. We can also set up a dedicated meeting between you and our experts to discuss our CRO services and your research needs.

Erwan BEZARD, PhD
CSO, AD/PD expert
MOTAC
Jeffrey HUBBARD, PhD
Head of Patch-Clamp laboratory
NEUROSERVICE
Bruno BUISSON, PhD
Co-Founder, President & CSO
NEUROSERVICES-ALLIANCE
& NEUROSERVICE
Bob PETROSKI, PhD
Scientific liaison
NEUROSERVICES-ALLIANCE
Jean-Charles BIZOT, PhD
CEO & Behavioral Pharmacologist
KEY-OBS
Fabrice TROVERO,PhD
GM & Behavioral Pharmacologist
KEY-OBS